A novel anti-galectin-9 immunotherapy limits the early progression of pancreatic neoplastic lesions in transgenic mice.

Front Immunol · 2023 · PMC10720041 · PMID 38098486

Europe PMC DOI

hedged sentence

0.0560

closest p · 1.1× alpha

0.0560

boldest claim

The sentences

nearly significantp= 0.056so close (0.05 < p ≤ 0.1)

The difference was nearly significant (p= 0.056) between mice who received isotype or anti-galectin-9.

also in 3,349 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.